Policy & Regulations

This channel includes news coverage of healthcare policy and regulations set by Congress, the states, Centers for Disease Control and Prevention (CDC), the Department of Health and Human Services (HHS), U.S. Food and Drug Administration (FDA), and medical associations and societies.

Massive spending bill passes final vote in Congress with Medicaid cuts intact
The 940-page document passed the House of Representatives in a 218 to 214 vote, and now heads to President Donald Trump’s desk. It contains a 20% cut to federal Medicaid funding, something Trump said he opposes.
Radiation in the cath lab: Tracking state-level regulations for cardiologists
Researchers hope these policies can be standardized in the future to help avoid confusion and improve clinician safety.
Doc groups say payer promises not enough to address care denials
MGMA and others who are part of the “Regulatory Relief Coalition” are urging Congress to continue pushing forward with the Improving Seniors’ Timely Access to Care Act.
Russian researcher strategizes on collaboration with China over healthcare AI
Have you ever wondered what China and Russia would talk about if they were to discuss AI in healthcare? It turns out they do just that—and a newly published academic paper straight out of the Russian Federation offers a glimpse into the dialogue.
10-second brain MRI scans possible with newly FDA-cleared deep learning reconstruction software
The artificial intelligence-enabled software offers accelerated acquisition times, improved image resolution and one-click workflows for technologists.

Dan Blumenthal, MD, MBA, chief quality officer at the Cardiovascular Associates of America, and a cardiologist at Massachusetts General Hospital, spoke at the Heart Rhythm Society (HRS) 2024 meeting business sessions on how changes in Medicare payments will impact electrophysiology and cardiology more broadly.

What cardiologists should expect as U.S. healthcare payment models evolve

Cardiologist Dan Blumenthal, MD, MBA, explains how changes in Medicare payments will greatly impact cardiology in the years ahead. In just a few short years, the business side of cardiology could look substantially different than it does today.

Novo Nordisk withdraws FDA application to expand use of weight loss drug

The Danish pharmaceutical company said it will resubmit its application in 2025 to have Wegovy approved for use in heart failure patients.

ACA premiums expected to rise 7% in 2025, report finds

A survey from KFF survey found the spike in cost will be mitigated by subsidies. However, the number of uninsured Americans could rise.

artificial intelligence AI money brain dollar

Radiology AI triage solution earns separate, additional Medicare hospital payment

The Centers for Medicare & Medicaid Services revealed the news under the 2025 Inpatient Prospective Payment System rule released on Aug. 1

cleveland clinic settles for failing to disclose research funding

Appeals court notches radiology another win in fight to fix No Surprises Act

The Radiology Business Management Association on Tuesday praised the ruling, calling it a “significant victory for patients and providers.”

doctor examines patient data on their tablet

FDA sees potential in new PET imaging agent for cardiac amyloidosis

Early evidence suggests a new PET imaging agent from California-based Attralus can help evaluate all varieties of systemic cardiac amyloidosis. It has now been granted the FDA's breakthrough therapy designation.

Bharath Krishnamurthy, a director of health policy and analytics at the American Hospital Association (AHA), factors that are leading to instability the U.S. healthcare system. #AHA #AmericanHospitalAssociation #CMS #Healthcare

Challenges to the financial stability of the American healthcare system

Bharath Krishnamurthy, director of health policy and analytics, American Hospital Association, explains factors leading to the economic instability of the U.S. healthcare system.

FDA denies pharma firm’s initial application for new kidney cancer imaging agent

Telix Pharmaceuticals Ltd. announced the news on July 31, with the decision applying to its TLX250-CDx investigational agent for clear cell renal cell carcinoma (brand name Zircaix).

Policy & Regulations

Massive spending bill passes final vote in Congress with Medicaid cuts intact

Radiation in the cath lab: Tracking state-level regulations for cardiologists

Doc groups say payer promises not enough to address care denials

Russian researcher strategizes on collaboration with China over healthcare AI

10-second brain MRI scans possible with newly FDA-cleared deep learning reconstruction software